Gastroesophageal Reflux Disease (GERD) Therapeutics – Pipeline Assessment and Market Forecasts to 2017
The industry analysis specialist, has released a new report, “Gastroesophageal Reflux Disease (GERD) Therapeutics – Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global GERD market. The report identifies the key trends shaping and driving the global GERD market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global GERD sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global Gastroesophageal Reflux Disease (GERD) market was worth $ 21.5 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 8.7% for the next eight years to reach $10.4 billion by 2017. The high projected rate of decline is primarily attributable to the patent expiries of all Proton Pump Inhibitors (PPIs) by the end of the forecast period. Increase in the treatment seeking population, the diagnosis population and long term anti-reflux maintenance therapy are expected to sustain the GERD market.
Scope
The scope of the report includes:
– Annualized global GERD market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.
– Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
– Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include H+/K+ ATPase Inhibitors, H2 antagonists, 5-HT4 receptor agonists and GABA-B receptor agonists.
– Analysis of the current and future market competition in the global GERD market. Key market players covered are AstraZeneca, XenoPort and Vecta.
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with GERD
For more information, please contact :
http://www.aarkstore.com/reports/Gastroesophageal-Reflux-Disease-GERD-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017-84341.html
Related Reports
Gastroesophageal Reflux Disease – Pipeline Review, Q1 2011
Gastroesophageal Reflux Disease Therapy Pipeline Report
Gastroesophageal Reflux Disease (GERD) Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Gastroesophageal reflux disease (GERD) – Pipeline Review, Q4 2010
Gastroesophageal Reflux Disease Therapy Area Pipeline Report
Gastroesophageal Reflux Disease Therapy Area Pipeline Report
Gastroesophageal Reflux Disease – Drug Pipeline Analysis and Market Forecasts to 2016
Digestive System Gastroesophageal Reflux Disease Therapy Area Pipeline Report
Contact : Minu
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email :[email protected]
Website : http://www.aarkstore.com
Blog:http://www.emarketreports.com
